Argos Therapeutics Inc (NASDAQ:ARGS) insider Charles A. Nicolette sold 100,250 shares of the business’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $0.16, for a total transaction of $16,040.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Argos Therapeutics Inc (NASDAQ ARGS) remained flat at $$0.16 on Friday. 2,251,745 shares of the stock traded hands, compared to its average volume of 5,213,525. Argos Therapeutics Inc has a one year low of $0.13 and a one year high of $5.55. The company has a debt-to-equity ratio of -1.46, a current ratio of 2.29 and a quick ratio of 2.29. The stock has a market cap of $14.26, a price-to-earnings ratio of -0.14 and a beta of 1.38.
An institutional investor recently bought a new position in Argos Therapeutics stock. Wasatch Advisors Inc. acquired a new stake in shares of Argos Therapeutics Inc (NASDAQ:ARGS) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned approximately 1.21% of Argos Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 18.35% of the company’s stock.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.